Literature DB >> 24670404

Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease.

Matthew R Weir1, Jeffrey C Fink.   

Abstract

PURPOSE OF REVIEW: Maintaining patient safety is a necessary step to improve healthcare delivery. Patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) have an increased frequency of adverse safety events largely because of medication errors. RECENT
FINDINGS: CKD and ESRD have several features which threaten patient safety. Reduced glomerular filtration rate affects the clearance of many medications and is also associated with several comorbidities such as diabetes, cardiovascular disease, metabolic bone disease, and anemia. These comorbidities of CKD often increase the complexity of treatment regimens. Patients with ESRD, requiring dialysis or transplantation, have an even greater potential for adverse safety events because of the reliance on renal replacement modalities and the frequent requirements of polypharmacy and potential drug-drug interactions.
SUMMARY: There is an important need to develop strategies to provide inpatient and outpatient management plans to limit the risk of adverse medication errors across a wide range of educational and socioeconomic backgrounds, and a critical need to develop a uniform set of standards for evaluating patient safety in CKD and ESRD as well as appropriate descriptions of the prototypical safety profiles of patients who have CKD, a kidney transplant, or who are on dialysis.

Entities:  

Mesh:

Year:  2014        PMID: 24670404     DOI: 10.1097/01.mnh.0000444912.40418.45

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  16 in total

1.  American Society of Nephrology quiz and questionnaire 2014: acid-base and electrolyte disorders.

Authors:  Mitchell H Rosner; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-23       Impact factor: 8.237

2.  Associations Between Polypharmacy, Symptom Burden, and Quality of Life in Patients with Advanced, Life-Limiting Illness.

Authors:  Yael Schenker; Seo Young Park; Kwonho Jeong; Jennifer Pruskowski; Dio Kavalieratos; Judith Resick; Amy Abernethy; Jean S Kutner
Journal:  J Gen Intern Med       Date:  2019-02-04       Impact factor: 5.128

3.  Multiple medication (polypharmacy) and chronic kidney disease in patients aged 60 and older: a pharmacoepidemiologic perspective.

Authors:  Ankit Sutaria; Longjian Liu; Ziauddin Ahmed
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-02-25

Review 4.  Maintaining safety in the dialysis facility.

Authors:  Alan S Kliger
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

5.  Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013-2017.

Authors:  Julie M Paik; Min Zhuo; Cassandra York; Theodore Tsacogianis; Seoyoung C Kim; Rishi J Desai
Journal:  Am J Nephrol       Date:  2021-11-23       Impact factor: 3.754

6.  Accurate Medication Adherence Measurement Using Administrative Data for Frequently Hospitalized Patients.

Authors:  Rafia S Rasu; Suzanne L Hunt; Junqiang Dai; Huizhong Cui; Milind A Phadnis; Nishank Jain
Journal:  Hosp Pharm       Date:  2020-06-02

Review 7.  Prescribing for patients on dialysis.

Authors:  Brendan Smyth; Ceridwen Jones; John Saunders
Journal:  Aust Prescr       Date:  2016-02-01

8.  Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.

Authors:  Vlado Perkovic; Robert Toto; Mark E Cooper; Johannes F E Mann; Julio Rosenstock; Darren K McGuire; Steven E Kahn; Nikolaus Marx; John H Alexander; Bernard Zinman; Egon Pfarr; Sven Schnaidt; Thomas Meinicke; Maximillian von Eynatten; Jyothis T George; Odd Erik Johansen; Christoph Wanner
Journal:  Diabetes Care       Date:  2020-05-22       Impact factor: 19.112

9.  Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients.

Authors:  Hadi Molanaei; Abdul Rashid Qureshi; Olof Heimbürger; Bengt Lindholm; Ulf Diczfalusy; Björn Anderstam; Leif Bertilsson; Peter Stenvinkel
Journal:  BMC Pharmacol Toxicol       Date:  2018-06-25       Impact factor: 2.483

10.  Polypharmacy and Medication-Related Problems in Hemodialysis Patients: A Call for Deprescribing.

Authors:  Majed Alshamrani; Abdullah Almalki; Mohamed Qureshi; Oyindamola Yusuf; Sherine Ismail
Journal:  Pharmacy (Basel)       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.